Bristol Myers Squibb Co (BMY) Non-Current Deffered Revenue (2009 - 2019)

Bristol Myers Squibb (BMY) has reported Non-Current Deffered Revenue for 11 consecutive years, with $448.0 million the latest figure, recorded in Q1 2019.

• In Q1 2019, Non-Current Deffered Revenue changed 0.22% year-over-year to $448.0 million; the TTM figure through Mar 2019 stood at $448.0 million (changed 0.22% YoY), while the FY2018 annual figure was $468.0 million, up 3.08% from the prior year.
• Non-Current Deffered Revenue declined to $448.0 million in Q1 2019 per BMY's latest filing, from $468.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $697.0 million in Q1 2015 and bottomed at $447.0 million in Q1 2018.
• Historically, Non-Current Deffered Revenue has averaged $542.5 million across 5 years, with a median of $528.0 million in 2017.
• Annual changes were most pronounced in 2015 — Non-Current Deffered Revenue sank 35.99% — and 2018, when it rose 3.08%.
• Bristol Myers Squibb's Non-Current Deffered Revenue stood at $586.0 million in 2015, then fell by 6.66% to $547.0 million in 2016, then declined by 17.0% to $454.0 million in 2017, then gained by 3.08% to $468.0 million in 2018, then declined by 4.27% to $448.0 million in 2019.
• Business Quant data shows BMY's Non-Current Deffered Revenue at $448.0 million in Q1 2019, $468.0 million in Q4 2018, and $486.0 million in Q3 2018.